Associated Genetic Biomarkers
Protein tyrosine kinase 7 (inactive) (PTK7) is a gene that encodes a receptor protein tyrosine kinase that does not have catalytic tyrosine kinase activity. The protein functions in the Wnt signaling pathway and cell processes such as polarity and adhesion. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
PTK7 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PTK7 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PTK7 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is PTK7 Expression .
Pf-06647020 is the most frequent therapy in trials with PTK7 as an inclusion criteria .
Significance of PTK7 in Diseases
Non-Small Cell Lung Carcinoma +
PTK7 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTK7 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.